MAPT and Alzheimer disease: Indeed, pathology-based studies are very rare but necessary to estimate the proportion of false-positive and false-negative cases against pathology, which will inform us about how many times clinicians will encounter a “true” AD (or non-AD) patient with inconsistent/wrong tau-PET or amyloid-PET (or both) scans.